Barriers to Providing Health Services for HIV/AIDS, Hepatitis C Virus Infection and Sexually Transmitted Infections in Substance Abuse Treatment Programs in the United States

Overview

Journal J Addict Dis

Publisher Informa Healthcare

Date 2011 Apr 15

PMID 21491291

Citations 21

Authors

Edmund J Bini

Steven Kritz

Lawrence S Brown Jr

Jim Robinson

Don Alderson

John Rotrosen

Affiliations

Soon will be listed here.

Abstract

We sought to identify barriers to offering services for HIV/AIDS, hepatitis C virus, and sexually transmitted infections in substance abuse treatment programs. We surveyed treatment program administrators and clinicians within the National Drug Abuse Treatment Clinical Trials Network to evaluate the availability of medical and non-medical services for patients with or at risk for acquiring these infections. A substantial proportion of programs do not offer services (particularly medical services) for these infections. The most commonly cited barriers were funding, health insurance benefits, patient acceptance, and staff training. The findings highlight a missed opportunity to positively impact these infectious disease epidemics.

Citing Articles

A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs.

Frimpong J, Parish C, Feaster D, Gooden L, Nelson M, Matheson T Trials. 2023; 24(1):609.

PMID: 37749635 PMC: 10521543. DOI: 10.1186/s13063-023-07602-8.

A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs.

Frimpong J, Parish C, Feaster D, Gooden L, Matheson T, Haynes L Res Sq. 2023; .

PMID: 37461594 PMC: 10350190. DOI: 10.21203/rs.3.rs-3059783/v1.

Systematic review of guidelines for managing physical health during treatment for substance use disorders: Implications for the alcohol and other drug workforce.

Osborne B, Larance B, Ivers R, Deane F, Robinson L, Kelly P Drug Alcohol Rev. 2022; 41(6):1367-1390.

PMID: 35765725 PMC: 9539873. DOI: 10.1111/dar.13504.

Hepatitis C testing and treatment uptake among young people who use opioids in New York City: A cross-sectional study.

Kapadia S, Katzman C, Fong C, Eckhardt B, Guarino H, Mateu-Gelabert P J Viral Hepat. 2020; 28(2):326-333.

PMID: 33141503 PMC: 8207521. DOI: 10.1111/jvh.13437.

Building the Case for Localized Approaches to HIV: Structural Conditions and Health System Capacity to Address the HIV/AIDS Epidemic in Six US Cities.

Panagiotoglou D, Olding M, Enns B, Feaster D, Del Rio C, Metsch L AIDS Behav. 2018; 22(9):3071-3082.

PMID: 29802550 PMC: 6076864. DOI: 10.1007/s10461-018-2166-6.

References

Weinstock H, Berman S, Cates Jr W . Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004; 36(1):6-10. DOI: 10.1363/psrh.36.6.04. View

Plitt S, Garfein R, Gaydos C, Strathdee S, Sherman S, Taha T . Prevalence and correlates of chlamydia trachomatis, neisseria gonorrhoeae, trichomonas vaginalis infections, and bacterial vaginosis among a cohort of young injection drug users in Baltimore, Maryland. Sex Transm Dis. 2005; 32(7):446-53. DOI: 10.1097/01.olq.0000154567.21291.59. View

Reback C, Larkins S, Shoptaw S . Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. AIDS Behav. 2004; 8(1):87-98. DOI: 10.1023/b:aibe.0000017528.39338.75. View

Kral A, Bluthenthal R, Booth R, Watters J . HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998; 88(1):108-13. PMC: 1508387. DOI: 10.2105/ajph.88.1.108. View

Anderson J, Wilson R, Barker P, Doll L, Jones T, Holtgrave D . Prevalence of sexual and drug-related HIV risk behaviors in the U.S. adult population: results of the 1996 National Household Survey on Drug Abuse. J Acquir Immune Defic Syndr. 1999; 21(2):148-56. View

Metzger D, Navaline H . HIV prevention among injection drug users: the need for integrated models. J Urban Health. 2004; 80(4 Suppl 3):iii59-66. PMC: 3456261. DOI: 10.1093/jurban/jtg083. View

Schroeder J, Epstein D, Umbricht A, Preston K . Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav. 2005; 31(5):868-79. DOI: 10.1016/j.addbeh.2005.07.009. View

Brown Jr L, Kritz S, Goldsmith R, Bini E, Rotrosen J, Baker S . Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2006; 30(4):315-21. PMC: 2535811. DOI: 10.1016/j.jsat.2006.02.006. View

Hubbard R, Craddock S, Anderson J . Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat. 2003; 25(3):125-34. DOI: 10.1016/s0740-5472(03)00130-2. View

10.

Bachmann L, Lewis I, Allen R, Schwebke J, Leviton L, SIEGAL H . Risk and prevalence of treatable sexually transmitted diseases at a Birmingham substance abuse treatment facility. Am J Public Health. 2000; 90(10):1615-8. PMC: 1446369. DOI: 10.2105/ajph.90.10.1615. View

11.

Armstrong G, Wasley A, Simard E, McQuillan G, Kuhnert W, Alter M . The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10):705-14. DOI: 10.7326/0003-4819-144-10-200605160-00004. View

12.

Strauss S, Astone J, Des Jarlais D, Hagan H . A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug Alcohol Depend. 2004; 73(3):227-36. DOI: 10.1016/j.drugalcdep.2003.08.009. View

13.

Pollack H, DAunno T, Lamar B . Outpatient substance abuse treatment and HIV prevention: an update. J Subst Abuse Treat. 2005; 30(1):39-47. DOI: 10.1016/j.jsat.2005.09.002. View

14.

Woody G, Gallop R, Luborsky L, Blaine J, Frank A, Salloum I . HIV risk reduction in the National Institute on Drug Abuse Cocaine Collaborative Treatment Study. J Acquir Immune Defic Syndr. 2003; 33(1):82-7. DOI: 10.1097/00126334-200305010-00012. View

15.

Metzger D, Navaline H, Woody G . Drug abuse treatment as AIDS prevention. Public Health Rep. 1998; 113 Suppl 1:97-106. PMC: 1307732. View

16.

Santibanez S, Garfein R, Swartzendruber A, Purcell D, Paxton L, Greenberg A . Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. J Urban Health. 2006; 83(1):86-100. PMC: 2258331. DOI: 10.1007/s11524-005-9009-2. View

17.

Strauss S, Falkin G, Vassilev Z, Des Jarlais D, Astone J . A nationwide survey of hepatitis C services provided by drug treatment programs. J Subst Abuse Treat. 2002; 22(2):55-62. DOI: 10.1016/s0740-5472(01)00213-6. View

18.

Francis H . Substance abuse and HIV infection. Top HIV Med. 2003; 11(1):20-4. View

19.

. Twenty-five years of HIV/AIDS--United States, 1981-2006. MMWR Morb Mortal Wkly Rep. 2006; 55(21):585-9. View

20.

Battjes R, Pickens R, Brown Jr L . HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: an update. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10(1):90-6. View